The Economics of Clinical Trials

How clinical trial phases work, why they are so costly, and India's changing role as a trial destination.

Clinical trials test whether a medicine is safe and works in people. They are the most expensive part of drug development.

The phases

Phase 1: a small group, often healthy volunteers, tests safety and dosage.
Phase 2: a few hundred patients test whether the drug works and its side effects.
Phase 3: hundreds to thousands of patients compare the drug with existing treatments or placebo.

Phase 3 trials can cost hundreds of millions of dollars.

Why they are expensive

Recruiting patients, often across many countries.
Doctors, hospitals and monitoring.
Long follow-up to see effects over time.
Data management and regulatory requirements.

India’s role

India’s large patient population and lower costs made it attractive for trials in the 2000s. After reports of unethical practices, including poor consent, trial numbers fell. India tightened rules, and the New Drugs and Clinical Trials Rules, 2019 set clearer timelines, compensation for injuries and ethics requirements, aiming to rebuild trial activity safely.

Innovations

Adaptive trials change design as results come in.
Decentralised trials use remote monitoring.
Real-world data supplements trials.

The phase 3 gamble

A company spends years and huge sums on a phase 3 trial of a heart drug. It fails to beat the existing treatment. The entire investment is lost, which is why investors watch trial results closely.

Thinking trials are a formality

Many drugs fail in phase 2 or 3. Trials are where most development money is spent and lost.

Key takeaways

Trials run in three main phases, from safety to large comparisons.
Phase 3 trials can cost hundreds of millions of dollars.
India tightened trial rules after ethics concerns, with 2019 rules setting clearer standards.
Adaptive and decentralised trials aim to cut costs.